These two pathways are known to play opposing roles in immune regulation: BTLA/HVEM signaling acts as an inhibitory checkpoint that limits T cell activation, while HVEM/LIGHT activates immune responses. In autoimmune diseases, where immune responses are overactive, inhibition of the HVEM/LIGHT signaling pathway could help dampen inflammation. This evidence concerns the gene BTLA and autoimmune disease.